Onyx Bridge Wealth Group LLC Trims Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Share It:

ChatGPT Perplexity WhatsApp LinkedIn X Grok Google AI

Onyx Bridge Wealth Group LLC lessened its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 5.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund Owned 2,101 shares of the company’s stock after selling 118 shares during the quarter. Onyx Bridge Wealth Group LLC’s holdings in Johnson & Johnson were worth $342,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of JNJ. DORCHESTER WEALTH MANAGEMENT Co raised its stake in shares of Johnson & Johnson by 8.6% during the first quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock worth $14,975,000 after purchasing an additional 5,327 shares during the last quarter. Cantor Fitzgerald Investment Advisor LP raised its stake in shares of Johnson & Johnson by 88.9% during the first quarter. Cantor Fitzgerald Investment Advisor LP now owns 175,194 shares of the company’s stock worth $31,049,000 after purchasing an additional 82,429 Shares during the last quarter. Rather & Kittrell Inc. raised its stake in shares of Johnson & Johnson by 78.6% during the first quarter. Rather & Kittrell Inc. now owns 2,825 shares of the company’s stock worth $500,000 after purchasing an 24 additional 3, the last quarter. Mercer Global Advisors Inc. ADV raised its stake in shares of Johnson & Johnson by 12.3% duri ng the first quarter. Mercer Global Advisors Inc. ADV now owns 387,236 shares of the company’s stock worth $68,630,000 after purchasing an additional 42,318 shares during the last quarter. Finally, Insight Inv LLC grew its holdings5% by John & John quarter. Insight Inv LLC now owns 11,664 shares of the company’s stock worth $2,067,000 after acquiring an additional 632 shares during the period. Hedge funds and other institutional investors own 68.59% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on JNJ. Morgan Stanley cut their price objective on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a research report on Tuesday, December 6th. Credit Suisse Group began coverage on Johnson & Johnson in a research report on Thursday, November 17th. They issued a “neutral” rating and a $170.00 price objective for the company. StockNews.com began coverage on Johnson & Johnson in a research report on Wednesday, October 12th. They issued a “strong-buy” rating for the company. Raymond James cut their price objective on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research report on Wednesday, October 19th. Finally, Atlantic Securities cut their price objective on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a research report on Wednesday, October 19th. Seven analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $182.42.

Johnson & Johnson Trading Up 1.1%

Shares of JNJ stock opened at $177.68 on Thursday. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37. The stock has a market cap of $464.54 billion, a P/E ratio of 24.75, a P/E/G ratio of 3.48 and a beta of 0.57. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The business has a fifty day simple moving average of $173.80 and a 200-day simple moving average of $171.22.

Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings data on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, beating analysts’ consensus estimates of $2.49 by $0.06. The business had revenue of $23.79 bill the quarter, compared to analyst estimates of $23.44 billion. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The business’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same quarter last year, the company earned $2.60 earnings per share. On average, analysts forecast that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd were paid a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis of 2.5 a dividend %. The ex-dividend date was Monday, November 21st. Johnson & Johnson’s payout ratio is currently 62.95%.

Johnson & Johnson declared that its board has approved a share repurchase program on Wednesday, September 14th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the company to repurchase up to 1.2% mark of its purchases open stock. Stock repurchase programs are generally an indication that the company’s board of directors believes its stock is undervalued.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 76,923 shares of the firm’s stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $176.78, for a total value of $13,598,447.94. The executive vice president now directly owns 126,456 shares of the company’s stock, valued at approximately $22,354,891.68. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Johnson & Johnson. Taniert Jensert news, LEV sold 76,923 shares of the firm’s stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $176.78, for a total value of $13,598,447.94. Following the sale, the executive vice president now directly 26 of 6 owns 6 stock, valued at approximately $22,354,891.68. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Joseph J. Wolk sold 14,781 shares of the firm’s stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total value of $2,654,667.60. Following the completion of the sale, the chief financial officer now directly owns 35,812 shares in the company. The disclosure for this sale can be found here. Insiders have sold a total of 300,750 shares of company stock valued at $52,311,677 over the last quarter. Insiders own 0.35% of the company’s stock.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby INTER ISTER brands; oral care under the Lbrs skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Subscribe to Updates

What's Hot